Handelsavisen
prelaunch
Companies Healthcare AGPU.O
AG
AGPU.O NASDAQ Biotechnology & Life-Science Tools

Axe Compute Inc

$8,55
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
47,4M USD
P/E
EV / Rev
Div yield
Op margin
-144 409,1 %
ROE
-488,5 %
Net margin
-186 059,4 %
Debt / equity
0,00
Beta
52w range
Volume
6
Day range
Prev close
$6,92
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Axe Compute Inc is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.

Business. Axe Compute Inc (AGPU.O) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ exchange.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-488,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AGPU.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AGPU.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Axe Compute Inc (AGPU.O) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ exchange.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Axe Compute Inc exhibits a highly leveraged equity structure, with a market price of $5.55 per share and a market capitalization of $30.74 million. The company's price-to-book ratio of 0.64 suggests that the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. The enterprise value to revenue ratio of 246.26 is significantly higher than typical industry benchmarks, reflecting a high valuation relative to its current revenue base.

    Profitability metrics for Axe Compute Inc are deeply negative, with a return on equity of -4.885% and a return on assets of -4.4073%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income of -$180.92 million and net income of -$233.10 million further underscore the company's financial distress. The gross profit margin of 42.03% is relatively high, but this is offset by substantial operating and non-operating expenses.

    Geographically and segment-wise, Axe Compute Inc's revenue concentration is not explicitly detailed in the available data. However, the company's operations are primarily focused on healthcare diagnostics, with no significant diversification across business lines or regions. This lack of diversification could expose the company to sector-specific risks, particularly in the biotechnology and medical research fields.

    The company's growth trajectory is concerning, with a significant decline in operating cash flow of -$9.96 million and a free cash flow of -$265.35 million. The capital expenditure of -$32.62 million indicates a heavy investment in infrastructure, which may not be yielding positive returns at this time. The outlook for the current fiscal year is negative, with no clear signs of improvement in the near term.

    Risk factors for Axe Compute Inc include a medium liquidity risk, as indicated by the current ratio of 10.02, which suggests the company has sufficient current assets to cover its current liabilities. However, the company's net cash position is negative after accounting for total debt, which could pose a liquidity challenge. The dilution risk is currently low, but the company's financial performance and capital structure may change this outlook in the future.

    Recent events and filings indicate that Axe Compute Inc is facing significant financial challenges, with a last actual EPS of -$34.80 and a last actual revenue of $1.624 million. These figures highlight the company's struggle to generate positive earnings and revenue, which could impact investor confidence and future funding opportunities.

    Key takeaways
    • Axe Compute Inc is operating at a significant loss, with a net income of -$233.10 million and a return on equity of -4.885%.
    • The company's market valuation is high relative to its revenue, with an enterprise value to revenue ratio of 246.26.
    • The company's liquidity position is medium, with a current ratio of 10.02, but it has a negative net cash position after accounting for total debt.
    • Axe Compute Inc's growth trajectory is negative, with a substantial decline in operating and free cash flow.
    • The company's financial performance and capital structure may increase dilution risk in the future.
    • Recent financial filings indicate a significant decline in earnings and revenue, which could impact investor confidence.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8,55
    Market cap
    $30.7M
    Enterprise value
    $30.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.6x
    P / Tangible book
    0.6x
    Tangible book
    $47.7M
    Net cash
    -$108.0k
    Current ratio
    10.0
    Debt / equity
    0.0
    ROA
    -4.4%
    ROE
    -4.9%
    Cash conversion
    4.0%
    CapEx / revenue
    -260.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setAGPU 0,0% · rank #70 of 78

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Suppliers1

    Supply chain

    Vendors → AGPU ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSAGPUAGPUAxe Compute Inc1 entityNVIDIA CORPORATIONSemiconductorsUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs AGPU · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    vs self
    Div yield
    vs self
    ROE
    21,9 %
    +510,4 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    +483,9 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    vs self
    Div yield
    vs self
    ROE
    75,4 %
    +563,9 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    vs self
    Div yield
    vs self
    ROE
    8,4 %
    +496,9 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +583,8 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    vs self
    Div yield
    vs self
    ROE
    8,5 %
    +497,0 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    vs self
    Div yield
    vs self
    ROE
    22,7 %
    +511,2 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    +338,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-144 409,1 %Bottom quartile
    Net Margin-186 059,4 %Bottom quartile
    ROE-488,5 %Bottom quartile
    Capex / Rev-26 035,1 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,04Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 025 000 sh3 grants3 insiders
    • Yaukey-Witter Jeremy ReeseCo-Chief Financial Officer · Non-Qualified Stock Options → Common StockAcquired 225 000 @ $3,51grant · 2026-04-16
    • Okamoto Kyle RobertPresident · Non-Qualified Stock Options → Common StockAcquired 300 000 @ $1,62grant · 2026-04-01
    • MIGLINO CHRISTOPHERDirector, CEO and Director · Non-Qualified Stock Options → Common StockAcquired 500 000 @ $2,44grant · 2026-02-09

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Axe Compute Inc Market data — financials · 2026-05-27
    • Axe Compute Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $010 insiders · last 365d
    • Zhu TheodoreDirector · Common StockOther 11 250 @ $6,61$74K · 2026-05-29
    • Zhu TheodoreDirector · Common StockOther 3 750 @ $6,61$25K · 2026-05-28
    • Blacher JoshuaCo-Chief Financial Officer · Common StockOther 9 389 · 2026-05-14
    • Hawryluk MatthewDirector · Common StockOther 6 782 · 2026-04-20
    • Zhu TheodoreDirector · Common StockOther 5 144 · 2026-04-20
    • Nuzum Charles Lee SrDirector · Common StockOther 14 082 · 2026-04-20
    • ST. CLAIR GREGORY SRDirector · Common StockOther 9 419 · 2026-04-20
    • HANDLEY DANIEL EDirector · Common StockOther 5 663 · 2026-04-20
    • Rao VeenaDirector · Common StockOther 4 197 · 2026-03-06
    • Matthews ShawnDirector · Common StockOther 1 166 · 2026-03-06
    • Vennare Raymond FDirector, Chief Executive Officer · Common StockOther 6 758 @ $2,59$18K · 2026-02-05
    • Vennare Raymond FDirector, Chief Executive Officer · Common StockOther 20 000 · 2025-12-10
    • Vennare Raymond FDirector, Chief Executive Officer · Common StockOther 2 373 @ $5,90$14K · 2025-11-28
    • Rao VeenaDirector · Common StockOther 64 680 · 2025-09-09
    • CHUNG-WELCH NANCYDirector · Common StockOther 64 680 · 2025-09-09
    • HANDLEY DANIEL EDirector · Common StockOther 64 680 · 2025-09-09
    • Hawryluk MatthewDirector · Common StockOther 64 680 · 2025-09-09
    • ST. CLAIR GREGORY SRDirector · Common StockOther 64 680 · 2025-09-09

    Short positioning

    509.9Kshares short+57.3% vs prior
    2.26days to cover
    50.1%short of daily vol
    19.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AGPU.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    AGPUNVDA.OBiotechnology
    This companySectorSuppliers

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): -488.5%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -1,740.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): -440.7%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -7.2%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.11xDerived (calculated)
    • Current ratio (FY 2025-12-31): 10.02xDerived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -1,655.8%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,663.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.1%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 61.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 23,651.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 963.6%Derived (calculated)
    • Operating income (annual): USD -180.92MSEC XBRL filing
    • Current liabilities (annual): USD 4.27MSEC XBRL filing
    • Total assets (annual): USD 52.89MSEC XBRL filing
    • Total liabilities (annual): USD 5.17MSEC XBRL filing
    • Net income (annual): USD -233.1MSEC XBRL filing
    • Cost of revenue (annual): USD 72.62KSEC XBRL filing
    • Capex (annual): USD 0SEC XBRL filing
    • Shareholders' equity (annual): USD 47.72MSEC XBRL filing
    • Cash & equivalents (annual): USD 10.79MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -13SEC XBRL filing
    • Shares outstanding (annual): 4.08MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-09FILINGFORM 8-K →
    2026-05-29 00:00 UTCINSIDER2 insider transactions — 2026-05
    2026-05-29INSIDERZhu Theodore transacted 11.2k sh — Director ~$74k
    2026-05-28INSIDERZhu Theodore transacted 3.8k sh — Director ~$25k
    2026-05-18FILINGFORM 8-K →
    2026-05-15FILINGFORM 8-K →
    2026-05-15FILING424B5 filing →
    2026-05-15FILINGFORM 10-Q →
    2026-05-14INSIDERBlacher Joshua transacted 9.4k sh — Co-Chief Financial Officer
    2026-05-12FILINGFORM 8-K →
    2026-04-22FILINGFORM 8-K →
    2026-04-20 00:00 UTCINSIDER7 insider transactions — 2026-04 2 derivative
    2026-04-20INSIDERHawryluk Matthew transacted 6.8k sh — Director
    2026-04-20INSIDERZhu Theodore transacted 5.1k sh — Director
    2026-04-20INSIDERNuzum Charles Lee Sr transacted 14.1k sh — Director
    2026-04-20INSIDERST. CLAIR GREGORY SR transacted 9.4k sh — Director
    2026-04-20INSIDERHANDLEY DANIEL E transacted 5.7k sh — Director
    2026-04-16FILINGFORM 8-K →
    2026-04-16INSIDERYaukey-Witter Jeremy Reese acquired 225.0k sh Non-Qualified Stock Options — Co-Chief Financial Officer
    2026-04-01FILINGFORM 8-K →
    2026-04-01INSIDEROkamoto Kyle Robert acquired 300.0k sh Non-Qualified Stock Options — President
    2026-03-31FILINGFORM 8-K →
    2026-03-31FILINGFORM 10-K →
    2026-03-09FILINGFORM 8-K →
    2026-03-06 00:00 UTCINSIDER2 insider transactions — 2026-03
    2026-03-06INSIDERRao Veena transacted 4.2k sh — Director
    2026-03-06INSIDERMatthews Shawn transacted 1.2k sh — Director
    2026-02-09 00:00 UTCINSIDER2 insider transactions — 2026-02 1 derivative
    2026-02-09INSIDERMIGLINO CHRISTOPHER acquired 500.0k sh Non-Qualified Stock Options — Director, CEO and Director
    2026-02-05INSIDERVennare Raymond F transacted 6.8k sh — Director, Chief Executive Officer ~$18k
    2025-12-10 00:00 UTCINSIDER1 insider transaction — 2025-12
    2025-12-10INSIDERVennare Raymond F transacted 20.0k sh — Director, Chief Executive Officer
    2025-11-28 00:00 UTCINSIDER1 insider transaction — 2025-11
    2025-11-28INSIDERVennare Raymond F transacted 2.4k sh — Director, Chief Executive Officer ~$14k
    2025-09-09 00:00 UTCINSIDER5 insider transactions — 2025-09
    2025-09-09INSIDERRao Veena transacted 64.7k sh — Director
    2025-09-09INSIDERCHUNG-WELCH NANCY transacted 64.7k sh — Director
    2025-09-09INSIDERHANDLEY DANIEL E transacted 64.7k sh — Director
    2025-09-09INSIDERHawryluk Matthew transacted 64.7k sh — Director
    Showing the 40 most recent of 41 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage